ChemInform Abstract: A Novel Dioxabicyclo(3.3.1)nonane, a Key Intermediate in the Synthesis of Erythronolide B seco-Acid.

ChemInform ◽  
2010 ◽  
Vol 26 (11) ◽  
pp. no-no
Author(s):  
V. M. LYNCH ◽  
W.-C. LEE ◽  
S. F. MARTIN ◽  
B. E. DAVIS
Keyword(s):  
1978 ◽  
Vol 9 (42) ◽  
Author(s):  
E. J. COREY ◽  
S. KIM ◽  
S. YOO ◽  
K. C. NICOLAOU ◽  
L. S. JUN. MELVIN ◽  
...  

1992 ◽  
Vol 111 (6) ◽  
pp. 297-303 ◽  
Author(s):  
Luca Baumer ◽  
Ilaria Compagnari ◽  
Giordano Sala ◽  
Guido Sello
Keyword(s):  

2000 ◽  
Vol 44 (5) ◽  
pp. 1266-1275 ◽  
Author(s):  
Ignacio Aguirrezabalaga ◽  
Carlos Olano ◽  
Nerea Allende ◽  
Leticia Rodriguez ◽  
Alfredo F. Braña ◽  
...  

ABSTRACT A 9.8-kb DNA region from the oleandomycin gene cluster inStreptomyces antibioticus was cloned. Sequence analysis revealed the presence of 8 open reading frames encoding different enzyme activities involved in the biosynthesis of one of the two 2,6-deoxysugars attached to the oleandomycin aglycone:l-oleandrose (the oleW, oleV,oleL, and oleU genes) andd-desosamine (the oleNI and oleTgenes), or of both (the oleS and oleE genes). AStreptomyces albus strain harboring the oleG2glycosyltransferase gene integrated into the chromosome was constructed. This strain was transformed with two different plasmid constructs (pOLV and pOLE) containing a set of genes proposed to be required for the biosynthesis of dTDP-l-olivose and dTDP-l-oleandrose, respectively. Incubation of these recombinant strains with the erythromycin aglycon (erythronolide B) gave rise to two new glycosylated compounds, identified asl-3-O-olivosyl- andl-3-O-oleandrosyl-erythronolide B, indicating that pOLV and pOLE encode all enzyme activities required for the biosynthesis of these two 2,6-dideoxysugars. A pathway is proposed for the biosynthesis of these two deoxysugars in S. antibioticus.


1987 ◽  
Vol 28 (33) ◽  
pp. 3835-3838 ◽  
Author(s):  
A.F. Sviridov ◽  
M.S. Ermolenko ◽  
D.V. Yashunsky ◽  
V.S. Borodkin ◽  
N.K. Kochetkov*

1975 ◽  
Vol 97 (3) ◽  
pp. 654-655 ◽  
Author(s):  
E. J. Corey ◽  
K. C. Nicolaou ◽  
Lawrence S. Melvin
Keyword(s):  

Author(s):  
A. F. Sviridov ◽  
D. V. Yashunskii ◽  
M. S. Ermolenko ◽  
V. S. Borodkin ◽  
N. K. Kochetkov

Materials ◽  
2021 ◽  
Vol 14 (22) ◽  
pp. 6980
Author(s):  
Pranab K. Bhadra ◽  
Rachael N. Magwaza ◽  
Niroshini Nirmalan ◽  
Sally Freeman ◽  
Jill Barber ◽  
...  

Erythromycin A is an established anti-bacterial agent against Gram-positive bacteria, but it is unstable to acid. This led to an evaluation of erythromycin B and its derivatives because these have improved acid stability. These compounds were investigated for their anti-malarial activities, by their in silico molecular docking into segments of the exit tunnel of the apicoplast ribosome from Plasmodium falciparum. This is believed to be the target of the erythromycin A derivative, azithromycin, which has mild anti-malarial activity. The erythromycin B derivatives were evaluated on the multi-drug (chloroquine, pyrimethamine, and sulfadoxine)-resistant strain K1 of P. falciparum for asexual growth inhibition on asynchronous culture. The erythromycin B derivatives were identified as active in vitro inhibitors of asexual growth of P. falciparum with low micro-molar IC50 values after a 72 h cycle. 5-Desosaminyl erythronolide B ethyl succinate showed low IC50 of 68.6 µM, d-erythromycin B 86.8 µM, and erythromycin B 9-oxime 146.0 µM on the multi-drug-resistant K1 of P. falciparum. Based on the molecular docking, it seems that a small number of favourable interactions or the presence of unfavourable interactions of investigated derivatives of erythromycin B with in silico constructed segment from the exit tunnel from the apicoplast of P. falciparum is the reason for their weak in vitro anti-malarial activities.


Sign in / Sign up

Export Citation Format

Share Document